Chatham Capital Group’s Anika Therapeutics ANIK Stock Holding History

Chatham Capital Group’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-23,787	Closed	-$531K	–	173
2022 Q2	$531K	Buy	23,787 +30	+0.1%	+$669	0.12%	137
2022 Q1	$597K	Buy	23,757 +311	+1%	+$9.48K	0.12%	136
2021 Q4	$840K	Buy	23,446 +35	+0.1%	+$1.4K	0.15%	128
2021 Q3	$997K	Buy	23,411 +664	+3%	+$27.4K	0.19%	112
2021 Q2	$985K	Buy	22,747 +2	+0%	+$85	0.19%	114
2021 Q1	$928K	Buy	+22,745	New	+$863K	0.19%	113

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Chatham Capital Group's ANIK Position: Q3 2022 in Review

Chatham Capital Group sold out of Anika Therapeutics (ANIK) in Q3 2022, closing a stake of 23,787 shares — an estimated $531K sold.

Chatham Capital Group first reported a position in ANIK in Q1 2021 and held it in 6 quarters. The position peaked at $997K in Q3 2021. 121 funds tracked by Wall St. Rank hold ANIK as of Q3 2022.

Chatham Capital Group reported no remaining Anika Therapeutics position as of Q3 2022 after selling out during the quarter.
Chatham Capital Group sold 23,787 Anika Therapeutics shares in Q3 2022, an estimated $531K.
Chatham Capital Group first reported a position in Anika Therapeutics in Q1 2021 and held it in 6 quarters.
Chatham Capital Group's Anika Therapeutics position peaked at $997K in Q3 2021.
121 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2022.

Based on Chatham Capital Group's 13F filing for Q3 2022, filed 28 Oct 2022.